Vinod Ravi, MD, MS, MBA, Medical Oncologist and Associate Professor of Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses two-year findings from the phase 3 MANEUVER trial evaluating pimicotinib in adults with tenosynovial giant cell tumor (TGCT).
Understanding Tenosynovial Giant Cell Tumor
TGCT is a rare disease that affects approximately 11 in one million people in the U.S. It causes the tissue lining of the joints and tendon sheaths to grow abnormally, resulting in a noncancerous mass or tumor.
There are two types of TGCT: local or nodular form and diffuse form. The local or nodular form involves the tendons that support the joint, or one area of the joint, while the diffuse form involves more extensive areas of the joint and/or tendon sheath.
Dr. Ravi explained that in TGCT, a small proportion of neoplastic cells produce colony-stimulating factor 1 (CSF-1), which attracts inflammatory cells to the joint. The accumulation of those inflammatory cells damages the joint over time, causing pain, stiffness, reduced mobility, and long-term functional limitations.
Pimicotinib Demonstrates Durable Responses in the Phase 3 MANEUVER Trial
Dr. Ravi discussed findings from a two-year safety and efficacy update of the MANEUVER trial (NCT05804045) presented at the 2026 European Society for Medical Oncology (ESMO) Congress. MANEUVER was a phase 3, global, randomized, double-blind placebo-controlled study evaluating the efficacy and safety of pimicotinib.
Pimicotinib is a once-daily oral CSF-1 receptor inhibitor approved by the FDA for adults with symptomatic, unresectable TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity.
The original MANEUVER results demonstrated a 54% objective response rate (ORR) at week 25 compared with 3.2% for placebo.
In the two-year findings, pimicotinib demonstrated a Response Evaluation Criteria in Solid Tumors (RECIST) ORR of 76.2%. In addition:
- ORR by tumor volume score increased from 74.6% at one year to 77.8% at two years.
- Complete responses by RECIST increased from 1.6% at week 25 to 7.9% at two years.
- The two-year duration-of-response rate was 82%.
Dr. Ravi explained that the continued response demonstrates durable tumor reduction, with additional patients achieving meaningful responses over time.
Sustained Improvements in Pain, Mobility, and Quality of Life
The two-year safety and efficacy update also confirmed noticeable improvements in patient symptoms and physical function through week 97. More specifically, participants experienced a:
- 19.6% improvement in relative range of motion.
- 7.4-point increase in Patient-Reported Outcomes Measurement Information System (PROMIS) physical function scores.
- 3.9-point reduction in worst stiffness.
- 3.1-point reduction in worst pain.
Since restoring a sense of normalcy is a goal for many clinicians, Dr. Ravi said these functional improvements were notable. In many cases, pimicotinib let patients return to activities they’ve struggled with in the past, including exercising and picking up their children.
Safety Findings and Future Directions
Dr. Ravi shared that safety remained consistent between years one and two, with no new safety signals. A little over a quarter of participants (27%) experienced an adverse event requiring dose reduction, while 7.9% discontinued treatment because of adverse events.
The most common clinical adverse events included itching, facial swelling, rash, and swelling around the eyes. Because of these potential side effects, Dr. Ravi stressed the importance of optimizing treatment doses.
Looking ahead, Dr. Ravi identified potential neoadjuvant use before surgery and better ways to measure patient function as important focuses for future research. He noted that advances in wearable technology, such as devices that track patients’ activity and movement, could help clinicians better understand how TGCT affects daily function and guide treatment decisions.
In Their Own Words
“The unmet need has been to have multiple agents that are available with different side effect profiles so that you can match a particular patient to the right drug so that they do not get toxicity in this particular condition, which is not lethal. It only produces a quality-of-life decline due to the presence of the disease. Treatment should not introduce more morbidity into the quality of life of the patient.” – Vinod Ravi, MD, MS, MBA, Medical Oncologist and Associate Professor of Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center
For more information, visit: https://www.emdserono.com/us-en/company/news/press-releases/esmo-2026-emd-serono-highlights-10-19-2026.html
To learn morea bout TGCT and other rare musculoskeletal diseases, visit: https://checkrare.com/diseases/musculoskeletal-diseases/
